Lexaria Bioscience (LEXX) Expected to Announce Quarterly Earnings on Tuesday

Lexaria Bioscience (NASDAQ:LEXX) is anticipated to announce its earnings results before the market opens on Tuesday, April 8th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $0.14 million for the quarter.

Lexaria Bioscience (NASDAQ:LEXX) last posted its earnings results on Friday, January 10th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Lexaria Bioscience had a negative return on equity of 88.88% and a negative net margin of 1,473.04%. On average, analysts expect Lexaria Bioscience to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lexaria Bioscience Price Performance

Shares of NASDAQ:LEXX opened at $1.71 on Tuesday. The stock has a market capitalization of $30.02 million, a P/E ratio of -3.42 and a beta of 0.99. The business has a 50-day moving average of $1.60 and a two-hundred day moving average of $2.18. Lexaria Bioscience has a fifty-two week low of $1.15 and a fifty-two week high of $4.44.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright decreased their target price on Lexaria Bioscience from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, January 24th.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.